2.1. Design
This is a secondary analysis of a double-blind, randomized, sham-controlled, phase II, parallel-group pilot clinical trial. The original study is registered at www.clinicaltrials.gov (NCT04016272). A total of 120 eligible participants, who provided informed and written consent, were randomly assigned to one of two groups: active tDCS and sham tDCS, with each group comprising 60 participants (n = 60) (Figure 1). Participant assignment relied on the order of study entries and a pre-generated randomization list, which was created via SAS software (version 9.4) by a statistician uninvolved in the trial's clinical aspects. To achieve a covariate balance between the groups, covariate adaptive randomization was employed.
2.2. Participants
Eligible participants were individuals aged 50–85 who (1) had symptomatic knee OA diagnosed according to the American College of Rheumatology criteria (knee radiographs were utilized to determine the severity of OA using Kellgren-Lawrence scores); (2) experienced knee OA pain in the past three months, with an average pain score of at least 30 on a 0–100 numerical rating scale; (3) could speak and read English; and (4) had no plans to change pain medication regimens during the trial. According to the American College of Rheumatology criteria for classifying osteoarthritis, participants were required to meet at least three of six criteria, which included: age > 50 years, stiffness lasting < 30 min, presence of crepitus, bony tenderness, bony enlargement, and absence of palpable warmth.
Exclusion criteria encompassed medical conditions that could potentially impact result interpretation, pose safety concerns during assessments or tDCS procedures, or hinder the successful completion of the study protocol. Specific exclusions comprised individuals who (1) had undergone prosthetic knee replacement or non-arthroscopic surgery on the affected knee; (2) had a history of brain surgery, brain tumor, seizure, stroke, or intracranial metal implants; (3) were diagnosed with systemic rheumatic diseases such as rheumatoid arthritis, systemic lupus erythematosus, or fibromyalgia; (4) exhibited alcohol/substance abuse; (5) were currently undergoing treatment with sodium channel blockers, calcium channel blockers, or NMDA receptor antagonists; (6) demonstrated reduced cognitive abilities (i.e., a Mini-Mental Status Exam score ≤ 23) that could hinder comprehension of the study procedures; (7) were pregnant or breastfeeding; (8) had experienced psychiatric hospitalization in the past year; and (9) lacked access to the internet.
Participants were recruited from Southeast Texas by advertising the study at local institutions such as UTHealth and in nearby communities through flyers. Additionally, potential participants were directly identified and recruited from the UT Physicians Orthopedics Clinic.
2.3. Intervention
Active tDCS. The tDCS device was a “Soterix 1×1 tDCS mini-CT Stimulator” (Soterix Medical Inc., NY) equipped with headgear and 5×7-cm saline-soaked surface sponge electrodes. The sponge electrodes were fixed to the custom headgear, which was easily secured onto the participant’s head to ensure a simple and foolproof electrode setup [19]. This single-position headgear, clearly marked with labeled sponges, mitigates user error and ensures accurate montage placement. The anode was placed over the primary motor cortex (M1) and the cathode over the contralateral supraorbital area. Anodal stimulation over M1 activates various afferent and efferent neural circuits, leading to improvements in pain and psychological symptoms [20,21]. A constant current of 2 mA (subthreshold intensity) was applied for 20 min, with 30 s of ramp-up and 30 s of ramp-down to ensure reliable blinding [20], for each session, totaling 15 sessions over 3 weeks (five sessions per week).
Participants received comprehensive training on the usage of the tDCS device during their baseline visit; they were shown how to apply and operate the device, practiced under supervision, and received feedback until they were comfortable using it independently. Once the research staff had verified that the participant had understood all the details of the stimulation procedure, they provided the participant with a tDCS device and daily organized device kit, accompanied by a pictorial manual with written instructions. Participants could only undergo a stimulation session strictly after having received a unique unlock code from the research team. Once suitable contact quality had been achieved, they could then proceed to the next step, which is to initiate stimulation, albeit without altering the device’s settings. This device features double-blinding protocols that necessitate entering a five-digit code to initiate stimulation. Each unique code, intended to trigger the programmed stimulation sequence, is for one-time use and can only be activated once. Both the experimenter and participant were unaware of the group assignments. After entering the unlock code, the device displayed a countdown timer for the 20-min session. Once the time had elapsed, the device automatically switched off, and participants were instructed to remove and dispose of the sponges and securely store the equipment for the subsequent session.
Sham tDCS. For sham stimulation, the setup mirrored that of the active one. However, the stimulator was only activated for 30 s at the beginning and end of the session to replicate the sensory experience of active tDCS without delivering a sustained current, effectively concealing whether the stimulation was active or sham [22].
2.4. Measurements
Demographic data, including age, gender, body mass index (BMI; kg/m²), race, education, and marital status, as well as clinical data, including the index knee (the knee most affected), Kellgren-Lawrence score, and the average duration of osteoarthritis (months), were collected. The measures utilized to assess clinical pain intensity, pain interference, and pain catastrophizing are described below. Pain outcomes were evaluated over 3 weeks, with assessments at the end of each week after five sessions.
Numeric Rating Scale (NRS). The pain NRS is a subjective report on daily pain experiences, reflecting both the somatosensory and emotional dimensions of pain. The NRS was used by the participants to indicate a number between 0 (no pain) and 100 (the worst pain imaginable) to quantify their average pain over the past 24 hours. The NRS is a reliable and well-validated measure known for its ability to accurately detect changes in pain among adults with knee OA [23].
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale. The WOMAC Index is a validated tool utilized for assessing symptoms of knee OA, comprising 24 items categorized into three subscales: pain (5 items), stiffness (2 items), and functional disability (17 items) [24]. Each subscale demonstrates reliability and validity in evaluating knee OA patients [25-27]. Along with the NRS, average knee pain for the past 48 hours was measured by the pain subscale, which consisted of 5 items on a 0-4 Likert scale measuring the pain severity during walking, climbing stairs, sleeping, resting, and standing. The participants’ responses to each pain question were summed up to derive an aggregated score for pain intensity.
The Western Ontario and McMaster Universities Osteoarthritis (WOMAC) functional subscale. The functional subscale (17 items) has questions that cover everyday activities such as standing, walking, and using stairs. In this study, each participant's responses to these functional disability questions, rated on a 5-point scale (0 being none to 4 being extreme), were aggregated to produce a composite score for pain interference.
Pain Catastrophizing Scale (PCS). The PCS assesses participants' frequency of experiencing specific catastrophic thoughts or feelings when in pain across three dimensions: rumination (4 items), magnification (3 items), and helplessness (6 items) [28]. Each item is rated on a 5-point scale ranging from "not at all" (0) to "all the time" (4). The total score was obtained by summing the raw scores across all items. The PCS demonstrated adequate internal consistency, with subscale alphas ranging from 0.66 to 0.87 (α for all items = 0.87) [28], and its sensitivity to psychosocial interventions for chronic pain has been established [29,30].
2.5. Statistical Analysis
Descriptive statistics were used to characterize the study participants. Chi-square or Fisher’s exact test for categorical variables and the t-test for continuous variables were used to compare participant characteristics between the groups. Multi-group Latent Transition Analysis (LTA) was used to achieve our primary aim. All analyses were conducted using Mplus version 8.8 (Muthén and Muthén, Los Angeles, CA, USA). Supplementary Table 1 includes the Mplus syntax.
2.5.1. Latent Transition Analysis (LTA)
LTA constitutes a type of structural equation model that allows for the examination and description of changes in latent categorical variables (i.e., latent classes) over time (Collins & Lanza, 2010). In LTA, these latent classes are considered dynamic “statuses” rather than stable classifications, that people may move in and out of over time. LTA produces three sets of parameters: 1) a matrix of item-response probabilities at each time point (denoted as “ρ” parameters) that captures the likelihood of participants in each latent class to provide different responses to each continuous variable (e.g., mental health symptom), conditional on latent status membership; 2) a vector of latent status probabilities at Time 1 (“δ” parameters) describing the time-specific proportion of participants expected to belong to the latent class at each time point; and 3) matrices of transition probabilities (“τ” parameters) representing the probability of membership in a status at timepoint t dependent upon membership in a latent status at timepoint t−1.
In multi-group LTA, latent status probabilities (δ’s) and transition (τ’s) probabilities can be expressed as a function of a grouping variable, thus facilitating between-group comparisons of the prevalence of the latent statuses and incidence of transitions over time [31]. In the context of clinical trials, this approach enables the statistical evaluation of an intervention’s efficacy. Theoretically speaking, each set of the aforementioned parameters potentially varies across study groups. To ensure interpretability, each element of the ρ-parameter matrix at Time 1 should be constrained to equate to the corresponding element at subsequent times, such that status definition at each timepoint remains consistent over time, thereby imposing measurement invariance [32]. This helps stabilize estimation to improve status identification and interpretation [16]. Furthermore, this facilitates group comparisons of both latent status and transition probabilities (γ and τ parameters, respectively) [32].
2.5.2. Statistical Analysis in the Current Study
First, we fitted successive, unconditional LTA models to identify the optimal number of latent statuses (constructed based on the combinations of four pain measures). Models from 2–4 statuses were tested. The best-fitting model was selected based on statistical fit indices, such as the Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), Sample-size Adjusted BIC (SABIC), and Log-Likelihood (LL), and entropy [33]. Where fit statistics yielded contradictory information, we checked for interpretability and clinical meaning. After determining the best-fitting model, multi-group LTA was conducted to model the transition probabilities of latent statuses over time and compare these differences between the active and sham groups. Herein, regarding measurement invariance (same item-response probabilities), we assumed that no difference existed in the way latent statuses were constructed across the follow-ups. All analyses were performed with all available data points using the Full Information Maximum Likelihood estimation, accounting for indicator- and longitudinal-level missingness [34].